228 related articles for article (PubMed ID: 7737689)
21. HLA-DM and the MHC class II antigen presentation pathway.
Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
[TBL] [Abstract][Full Text] [Related]
22. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing.
Li P; Gregg JL; Wang N; Zhou D; O'Donnell P; Blum JS; Crotzer VL
Immunol Rev; 2005 Oct; 207():206-17. PubMed ID: 16181338
[TBL] [Abstract][Full Text] [Related]
23. Trafficking of MHC class II molecules in the late secretory pathway.
Hiltbold EM; Roche PA
Curr Opin Immunol; 2002 Feb; 14(1):30-5. PubMed ID: 11790530
[TBL] [Abstract][Full Text] [Related]
24. The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells.
Zwart W; Peperzak V; de Vries E; Keller AM; van der Horst G; Veraar EA; Geumann U; Janssen H; Janssen L; Naik SH; Neefjes J; Borst J
J Cell Sci; 2010 Nov; 123(Pt 21):3817-27. PubMed ID: 20971706
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation regulates the delivery of MHC class II invariant chain complexes to antigen processing compartments.
Anderson HA; Roche PA
J Immunol; 1998 May; 160(10):4850-8. PubMed ID: 9590232
[TBL] [Abstract][Full Text] [Related]
26. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
27. MHC class II molecules on the move for successful antigen presentation.
Rocha N; Neefjes J
EMBO J; 2008 Jan; 27(1):1-5. PubMed ID: 18046453
[TBL] [Abstract][Full Text] [Related]
28. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.
Villadangos JA; Driessen C; Shi GP; Chapman HA; Ploegh HL
EMBO J; 2000 Mar; 19(5):882-91. PubMed ID: 10698930
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
[TBL] [Abstract][Full Text] [Related]
30. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
[TBL] [Abstract][Full Text] [Related]
31. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
32. Assembly, transport, and function of MHC class II molecules.
Cresswell P
Annu Rev Immunol; 1994; 12():259-93. PubMed ID: 8011283
[TBL] [Abstract][Full Text] [Related]
33. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.
ten Broeke T; Wubbolts R; Stoorvogel W
Cold Spring Harb Perspect Biol; 2013 Dec; 5(12):a016873. PubMed ID: 24296169
[TBL] [Abstract][Full Text] [Related]
34. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
35. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.
Frauwirth K; Shastri N
Immunology; 2001 Apr; 102(4):405-15. PubMed ID: 11328374
[TBL] [Abstract][Full Text] [Related]
36. Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice.
Tourne S; van Santen HM; van Roon M; Berns A; Benoist C; Mathis D; Ploegh H
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1464-9. PubMed ID: 8643655
[TBL] [Abstract][Full Text] [Related]
37. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
38. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
[TBL] [Abstract][Full Text] [Related]
39. Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
Haque A; Hajiaghamohseni LM; Li P; Toomy K; Blum JS
Cell Immunol; 2007 Sep; 249(1):20-9. PubMed ID: 18067883
[TBL] [Abstract][Full Text] [Related]
40. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
